By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins today said that it has signed on investment firm Bloom Burton as an advisor to the company.

Bloom Burton, based in Toronto, will provide strategic and financial services, including an overview and analysis of potential opportunities, financial modeling, analysis of Miraculins' business plan, an overview and assessment of financing options, and strategic partnership opportunities, Miraculins said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.